Dr. Renschler Discusses Updated Results of the MPACT Study
Markus Renschler, MD, vice president, global head, Hematology Oncology Medical Affairs at Celgene, discusses updated results of the MPACT study, which examined nab-paclitaxel plus gemcitabine versus gemcitabine for patients with metastatic pancreatic cancer.
Renschler says the updated analysis shows a statistically significant improvement in overall survival (6.6 months to 8.7 months) in patients who received both nab-paclitaxel and gemcitabine.
The data also shows a tail at the end of the survival curve, Renschler says. The 2-year survival rate doubled from 5% to 10% and there are now 4-year survivals in the nab-paclitaxel gemcitabine arm.